Cargando…

Thyroid lobectomy is sufficient for differentiated thyroid cancer with upgraded risk after surgery

BACKGROUND: It is difficult to reliably distinguish between American Thyroid Association (ATA) low-risk and intermediate-risk differentiated thyroid cancer (DTC) before surgery. Therefore, physicians are faced with a dilemma regarding the necessity and timing of completion total thyroidectomy (CT) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Soon Min, Kim, Dong Gyu, Lee, Ji-Eun, Ho, Joon, Kim, Jin Kyong, Lee, Cho Rok, Kang, Sang-Wook, Lee, Jandee, Jeong, Jong Ju, Chung, Woong Youn, Nam, Kee-Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547714/
https://www.ncbi.nlm.nih.gov/pubmed/36221282
http://dx.doi.org/10.21037/gs-22-158
_version_ 1784805324634456064
author Choi, Soon Min
Kim, Dong Gyu
Lee, Ji-Eun
Ho, Joon
Kim, Jin Kyong
Lee, Cho Rok
Kang, Sang-Wook
Lee, Jandee
Jeong, Jong Ju
Chung, Woong Youn
Nam, Kee-Hyun
author_facet Choi, Soon Min
Kim, Dong Gyu
Lee, Ji-Eun
Ho, Joon
Kim, Jin Kyong
Lee, Cho Rok
Kang, Sang-Wook
Lee, Jandee
Jeong, Jong Ju
Chung, Woong Youn
Nam, Kee-Hyun
author_sort Choi, Soon Min
collection PubMed
description BACKGROUND: It is difficult to reliably distinguish between American Thyroid Association (ATA) low-risk and intermediate-risk differentiated thyroid cancer (DTC) before surgery. Therefore, physicians are faced with a dilemma regarding the necessity and timing of completion total thyroidectomy (CT) after thyroid lobectomy (TL). We evaluated proper surgical methods by analyzing oncologic outcomes of TL in patients with DTC whose risk had been upgraded after surgery. METHODS: We retrospectively reviewed the medical records of 1,702 patients with DTC who underwent TL and ipsilateral central lymph node (LN) dissection between January 2006 and December 2011. The patients were classified into Group A (n=1,159; low risk; ≤5 central LN metastases or the absence of pathologic microscopic capsular invasion) and Group B (n=543; upgraded intermediate risk after surgery; >5 central LN metastases or the presence of pathologic microscopic capsular invasion). We analyzed their clinicopathological characteristics and recurrence-free survival. RESULTS: All 32 patients who experienced recurrence underwent CT. After the first operation, the duration until reoperation in Groups A and B were 8.00±2.74 (range, 3.42–12.17) and 5.10±3.09 (range, 1.25–11.67) years, respectively. There was no significant difference in recurrence rates, disease-related mortality rates, or 10-year recurrence-free survival rates between the two groups. The mean follow-up durations in Groups A and B were 10.22±1.58 and 10.13±1.47 years, respectively. Univariate analysis showed that sex, age, tumor size, multifocality, extrathyroidal extension (ETE), and number of central LN metastases were not associated with recurrence after TL, although the rate of central LN metastases was. Multivariate analysis showed that sex, age, tumor size, multifocality, ETE, central LN metastases, and the number of central LN metastases were not associated with recurrence after TL, although multifocality was. CONCLUSIONS: TL with prophylactic central compartment neck dissection (CCND) is sufficient for patients with DTC whose risk is upgraded after surgery because they have a good prognosis at long-term follow-up. Larger-scale randomized clinical trials are required to confirm our findings.
format Online
Article
Text
id pubmed-9547714
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-95477142022-10-10 Thyroid lobectomy is sufficient for differentiated thyroid cancer with upgraded risk after surgery Choi, Soon Min Kim, Dong Gyu Lee, Ji-Eun Ho, Joon Kim, Jin Kyong Lee, Cho Rok Kang, Sang-Wook Lee, Jandee Jeong, Jong Ju Chung, Woong Youn Nam, Kee-Hyun Gland Surg Original Article BACKGROUND: It is difficult to reliably distinguish between American Thyroid Association (ATA) low-risk and intermediate-risk differentiated thyroid cancer (DTC) before surgery. Therefore, physicians are faced with a dilemma regarding the necessity and timing of completion total thyroidectomy (CT) after thyroid lobectomy (TL). We evaluated proper surgical methods by analyzing oncologic outcomes of TL in patients with DTC whose risk had been upgraded after surgery. METHODS: We retrospectively reviewed the medical records of 1,702 patients with DTC who underwent TL and ipsilateral central lymph node (LN) dissection between January 2006 and December 2011. The patients were classified into Group A (n=1,159; low risk; ≤5 central LN metastases or the absence of pathologic microscopic capsular invasion) and Group B (n=543; upgraded intermediate risk after surgery; >5 central LN metastases or the presence of pathologic microscopic capsular invasion). We analyzed their clinicopathological characteristics and recurrence-free survival. RESULTS: All 32 patients who experienced recurrence underwent CT. After the first operation, the duration until reoperation in Groups A and B were 8.00±2.74 (range, 3.42–12.17) and 5.10±3.09 (range, 1.25–11.67) years, respectively. There was no significant difference in recurrence rates, disease-related mortality rates, or 10-year recurrence-free survival rates between the two groups. The mean follow-up durations in Groups A and B were 10.22±1.58 and 10.13±1.47 years, respectively. Univariate analysis showed that sex, age, tumor size, multifocality, extrathyroidal extension (ETE), and number of central LN metastases were not associated with recurrence after TL, although the rate of central LN metastases was. Multivariate analysis showed that sex, age, tumor size, multifocality, ETE, central LN metastases, and the number of central LN metastases were not associated with recurrence after TL, although multifocality was. CONCLUSIONS: TL with prophylactic central compartment neck dissection (CCND) is sufficient for patients with DTC whose risk is upgraded after surgery because they have a good prognosis at long-term follow-up. Larger-scale randomized clinical trials are required to confirm our findings. AME Publishing Company 2022-09 /pmc/articles/PMC9547714/ /pubmed/36221282 http://dx.doi.org/10.21037/gs-22-158 Text en 2022 Gland Surgery. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Choi, Soon Min
Kim, Dong Gyu
Lee, Ji-Eun
Ho, Joon
Kim, Jin Kyong
Lee, Cho Rok
Kang, Sang-Wook
Lee, Jandee
Jeong, Jong Ju
Chung, Woong Youn
Nam, Kee-Hyun
Thyroid lobectomy is sufficient for differentiated thyroid cancer with upgraded risk after surgery
title Thyroid lobectomy is sufficient for differentiated thyroid cancer with upgraded risk after surgery
title_full Thyroid lobectomy is sufficient for differentiated thyroid cancer with upgraded risk after surgery
title_fullStr Thyroid lobectomy is sufficient for differentiated thyroid cancer with upgraded risk after surgery
title_full_unstemmed Thyroid lobectomy is sufficient for differentiated thyroid cancer with upgraded risk after surgery
title_short Thyroid lobectomy is sufficient for differentiated thyroid cancer with upgraded risk after surgery
title_sort thyroid lobectomy is sufficient for differentiated thyroid cancer with upgraded risk after surgery
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547714/
https://www.ncbi.nlm.nih.gov/pubmed/36221282
http://dx.doi.org/10.21037/gs-22-158
work_keys_str_mv AT choisoonmin thyroidlobectomyissufficientfordifferentiatedthyroidcancerwithupgradedriskaftersurgery
AT kimdonggyu thyroidlobectomyissufficientfordifferentiatedthyroidcancerwithupgradedriskaftersurgery
AT leejieun thyroidlobectomyissufficientfordifferentiatedthyroidcancerwithupgradedriskaftersurgery
AT hojoon thyroidlobectomyissufficientfordifferentiatedthyroidcancerwithupgradedriskaftersurgery
AT kimjinkyong thyroidlobectomyissufficientfordifferentiatedthyroidcancerwithupgradedriskaftersurgery
AT leechorok thyroidlobectomyissufficientfordifferentiatedthyroidcancerwithupgradedriskaftersurgery
AT kangsangwook thyroidlobectomyissufficientfordifferentiatedthyroidcancerwithupgradedriskaftersurgery
AT leejandee thyroidlobectomyissufficientfordifferentiatedthyroidcancerwithupgradedriskaftersurgery
AT jeongjongju thyroidlobectomyissufficientfordifferentiatedthyroidcancerwithupgradedriskaftersurgery
AT chungwoongyoun thyroidlobectomyissufficientfordifferentiatedthyroidcancerwithupgradedriskaftersurgery
AT namkeehyun thyroidlobectomyissufficientfordifferentiatedthyroidcancerwithupgradedriskaftersurgery